Effects of simvastatin on the expression of intercellular adhesion molecule-1 mRNA in neonatal brain with hypoxic-ischemic damage.
The goal of this paper is to report on the study of the mechanism of neural damage in neonatal cerebral cortex and hippocampus when hypoxic-ischemic brain damage (HIBD) occurs and the neural protective effects of simvastatin. One hundred forty-four 7-day-old SD rats of were randomly divided into four groups, i.e., sham operation group (sham group), normal saline control group (HIBD group), citicoline control group (CDPC group), and simvastatin-treated group. Each group was divided into six time points (0 h, 12 h, 24 h, 48 h, 72 h, and 7 days after HIBD or sham operation), and each time point included six rats. The expression of intercellular adhesion molecule-1 (ICAM-1) mRNA was determined semiquantitively by reverse transcription polymerase chain reaction (RT-PCR) in the cortex and hippocampus of neonatal rats at different times to determine the differences. The expression of ICAM-1 mRNA rose obviously 12 h after HIBD in the ischemic hemisphere, peaked at 24 h, and then decreased gradually. There was a remarkably lower expression in the CDPC group and simvastatin group compared with the HIBD group at 12 h, 24 h, 48 h, and 72 h. At 7 days, there was no significant difference between the simvastatin group and the sham group (P > 0.05), and at 72 h, simvastatin down-regulated the expression of ICAM-1 mRNA in cortex significantly more than did citicoline (P < 0.05). Both simvastatin and CDPC can relieve the damages of the brain in rats with HIBD. The protective mechanisms of simvastatin and citicoline are associated with their regulative effect on ICAM-1, and simvastatin is superior to citicoline.
Miao
Hongjun
H
Department of Pediatrics, Clinical Medical College of Southeast University, Nanjing 210009, P R. China.
Jiang
Li
L
Huang
Li
L
D000818:Animals; D000831:Animals, Newborn; D001483:Base Sequence; D001921:Brain / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D003566:Cytidine Diphosphate Choline / Q000494:pharmacology; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy* / Q000235:genetics*; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics*; D008297:Male; D036103:Nanotechnology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019821:Simvastatin / Q000494:pharmacology*
D018076:DNA, Complementary; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018696:Neuroprotective Agents; D012333:RNA, Messenger; D018799:Intercellular Adhesion Molecule-1; D003566:Cytidine Diphosphate Choline; D019821:Simvastatin